| ||Charles J. Rosser, MD, MBA |
Professor of Surgery
Translational Research Laboratory
Steve Goodison, PhD Co-Investigator
Virginia Urquidi, Ph.D. Co-Investigator
Wasia Rizwani, PhD Postdoctoral Scientist
Makito Miyake, MD, PhD Postdoctoral Scientist
Evan Gomes, PhD Postdoctoral Scientist
Shanti Ross, BS Laboratory Technician
| Charles J. Rosser, MD, MBA || Donna Schade |
| Translational Research Laboratory |
Cancer Research Institute
MD Anderson Cancer Center Orlando
6900 Lake Nona Blvd
Orlando, Florida 32827
| Phone: 407.266.7405 |
Dr. Charles Rosser studied at Fairleigh Dickinson University in Madison, New Jersey, to receive his B.S. in Biology. After attending Robert Wood Johnson Medical School to obtain his M.D., Dr. Rosser went to Wake Forest University School of Medicine to practice his residency and study urological oncology.
Project 1. Previously our laboratory clearly demonstrated that Bcl-2 over expression in prostatic tumors were associated with radiation resistance. Down regulation of Bcl-2 by viral gene therapy or small molecule inhibitors sensitized these tumors (in vitro and in vivo) to the effects of radiation. In these same experiments our laboratory discovered that tumoral Bcl-2 expression was associated with increased vascular endothelial growth factor (VEGF) expression and angiogenesis. In vitro studies confirmed that VEGF can not only increase proliferation of endothelial cells, but can increase expression of Bcl-2 in endothelial cells and stabilize Bcl-2 mRNA. Furthermore, Bcl-2 expression is regulated by several pathways (e.g., mTOR, PI3K, PKC, ERK).
Endothelial cells subjected to the environment of a Bcl-2 expressing tumor possess a unique molecular profile. Currently we are studying the effect of VEGF on the Bcl-2 promoter and we are further exploring the molecular profile of endothelial cells from Bcl-2 expressing tumors. In addition we are close to opening a neoadjuvant clinical trial combining a small molecule inhibitor of Bcl-2 with bevazicumab in subjects with localized high-risk prostate cancer.
Project 2. Much attention has turned to the association of infection and carcinogenesis. My laboratory has demonstrated a strain of Mycoplasma to be associated with prostate cancer. In addition a novel protein (p37) to this Mycoplasmal strain can: generate a unique molecular profile, increase the invasive nature, produce significant changes in proliferation and morphology in in vitro assays that are indicative of a more aggressive phenotype. Currently we are investigating the incidence of this infectious organism in normal subjects and subjects with prostate cancer and exploring the mechanism by which Mycoplasma inducing carcinogenesis/progression.
Project 3. Bladder cancer continues to be a major care to our healthcare system. Specifically individuals with non-invasive bladder cancer are routinely managed conservatively and will be monitored by routine visual bladder inspection. We hope to identify a panel of genes indicative of bladder cancer that may be used to screen or surveil for bladder cancer in a non-invasive manner. We have preliminary results of a unique molecular profile identified in the urine of subjects with bladder cancer. Currently we are prospectively validating our panel of tumor-associated genes in a large cohort of diverse individuals.
Urquidi V, Rosser CJ, Goodison S: Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis. Curr Med Chem 2012, (In Press).
Urquidi V, Kim J, Goodison S, Chang M, Dai Y, Rosser CJ: VEGF, CA9 and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection. Urology 2012, (In Press).
Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, Rosser CJ, Wood CG, Matin SF: Comprehensive Assessment of Quality of Life and Psychosocial Adjustment in Patients With Renal Tumors Undergoing Open, Laparoscopic and Nephron Sparing Surgery. J Urol 2012.
Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, Lubman DM, Goodison S: Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011, 17:3349-3359.
Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li CZ, Boehlein SK, Rosser CJ: Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer 2011, 11:233.
Sippel KH, Venkatakrishnan B, Boehlein SK, Sankaran B, Quirit JG, Govindasamy L, Agbandje-McKenna M, Goodison S, Rosser CJ, McKenna R: Insights into Mycoplasma genitalium metabolism revealed by the structure of MG289, an extracytoplasmic thiamine binding lipoprotein. Proteins 2011, 79:528-536.
Li CZ, Vandenberg K, Prabhulkar S, Zhu X, Schneper L, Methee K, Rosser CJ, Almeide E: Paper based point-of-care testing disc for multiplex whole cell bacteria analysis. Biosens Bioelectron 2011, 26:4342-4348.
Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, Rosser CJ, Su LM, Vieweg J, Kusmartsev S: Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 2011, 71:6400-6409.
Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ: Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol 2011, 29:421-429.
Rosser CJ, Nakamura K, Pendleton J, Anal S, Chang M, Kasraelan A, Yeung L: Utility of serial urinalyses and urinary cytology in the evaluation of patients with microscopic haematuria. West Afr J Med 2010, 29:384-387.
Rosser CJ, Goodison S: Today's discoveries to tomorrow's care: cancer biomarkers revisited. Foreword. Biomark Med 2010, 4:491-493.
Rosser CJ, Goodison S: CD24, a promising biomarker in NSCLC. Biomark Med 2010, 4:495.
Rosser CJ, Goodison S: From gene to protein expression: improving prognostication of DCIS. Biomark Med 2010, 4:496-497.
Rosser CJ, Goodison S: Novel approach for oral cancer biomarker discovery. Biomark Med 2010, 4:495-496.
Rosser CJ: Editorial comment. Urology 2010, 75:132; author reply 132-133.
Bovio IM, Al-Quran SZ, Rosser CJ, Algood CB, Drew PA, Allan RW: Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Histopathology 2010, 56:951-956.
Arakawa M, Nakamura K, Yamada Y, Rosser CJ, Tobiume M, Saito H, Hasegawa T, Honda N: Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report. BMC Urol 2010, 10:6.
Villicana P, Whiting B, Goodison S, Rosser CJ: Urine-based assays for the detection of bladder cancer. Biomark Med 2009, 3:265.
Urbanek C, Turpen R, Rosser CJ: Radical prostatectomy: Hospital volumes and surgical volumes - does practice make perfect? BMC Surg 2009, 9:10.
Turpen R, Rosser CJ: Focal therapy for prostate cancer: revolution or evolution? BMC Urol 2009, 9:2.
Sippel KH, Robbins AH, Reutzel R, Boehlein SK, Namiki K, Goodison S, Agbandje-McKenna M, Rosser CJ, McKenna R: Structural insights into the extracytoplasmic thiamine-binding lipoprotein p37 of Mycoplasma hyorhinis. J Bacteriol 2009, 191:2585-2592.
Sippel KH, Boehlein SK, Sakai Y, Quirit JG, Agbandje-McKenna M, Rosser CJ, McKenna R: Cloning, expression, purification, crystallization and preliminary X-ray analysis of Mycoplasma genitalium protein MG289. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009, 65:910-912.
Sakai Y, Goodison S, Kusmartsev S, Fletcher B, Eruslanov E, Cao W, Porvasnik S, Namiki K, Anai S, Rosser CJ: Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate 2009, 69:459-470.
Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S: Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009, 18:444-453.
Rosser CJ, Gaar M, Porvasnik S: Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? BMC Cancer 2009, 9:225.
Rosser CJ: Editorial comment. J Urol 2009, 182:2272; discussion 2273.
Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ: Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009, 69:1460-1469.
Namiki K, Kasraeian A, Yacoub S, Rosser CJ: Blunt apical dissection during anatomic radical retropubic prostatectomy. BMC Res Notes 2009, 2:20.
Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ: Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One 2009, 4:e6872.
Nakamura K, Yamada Y, Rosser CJ, Aoki S, Taki T, Honda N: Holmium YAG laser ablation of a hemangioma involving a lower pole renal calyx - using the new-generation flexible ureteroscope URF type P5: a case report. Cases J 2009, 2:7780.
Nakamura K, Kasraeian A, Iczkowski KA, Chang M, Pendleton J, Anai S, Rosser CJ: Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 2009, 9:12.
Genis C, Sippel KH, Case N, Cao W, Avvaru BS, Tartaglia LJ, Govindasamy L, Tu C, Agbandje-McKenna M, Silverman DN, et al: Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. Biochemistry 2009, 48:1322-1331.
Dahm P, Rosser CJ, McKiernan JM: Quality of care for testis cancer. Urol Oncol 2009, 27:448-453.
Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y: Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther 2008, 7:1864-1870.
Sippel KH, Robbins AH, Reutzel R, Domsic J, Boehlein SK, Govindasamy L, Agbandje-McKenna M, Rosser CJ, McKenna R: Structure determination of the cancer-associated Mycoplasma hyorhinis protein Mh-p37. Acta Crystallogr D Biol Crystallogr 2008, 64:1172-1178.
Rosser CJ: Prostate cancer--to screen, or not to screen, is that the question? BMC Urol 2008, 8:20.